461 articles in this topic
AICAR-driven AMPK activation rescues mitochondrial energy balance in hypoxic corneal cells, pointing to a new therapy for keratopathy.
New sensor data shows type 1 diabetics on ketogenic diets experience frequent, short-lived, asymptomatic ketosis episodes — mostly harmless.
A new review maps how tirzepatide's dual GIP/GLP-1 action reshapes metabolism across the pancreas, liver, gut, heart, kidneys, and brain.
People with schizophrenia exposed to the most nighttime light face 4x higher obesity odds and 3x higher hypertension odds.
A 5-year cohort study finds that CGM-derived time in range predicts arterial stiffness changes independently of HbA1c in type 2 diabetes.
Emerging evidence suggests GLP-1 receptor agonists like semaglutide may reduce cocaine craving and relapse by dampening dopamine signaling.
A large retrospective study finds GLP-1 receptor agonists significantly reduce AMD risk in both diabetic and obese patients.
A 10-year Korean cohort study finds GLP-1 receptor agonists don't raise psychiatric risk compared to DPP-4 inhibitors, but show modest signals vs SGLT2 inhibitors.
A traditional Chinese formula and its key compound GsRg1 restore brain insulin signaling in obese rats by activating hypothalamic self-cleaning pathways.
A large real-world study finds GLP-1 drugs cut anxiety and depression risk vs. older weight-loss meds — but tirzepatide raises insomnia flags.
A new Nature Metabolism review reveals how mitochondrial maintenance systems govern healthy aging — and how NAD+, AMPK, and caloric restriction may restore them.
A 30-week Pakistani multicentre study shows biosynthetic semaglutide delivers clinically meaningful glycemic and weight benefits in routine care.
